Efficacy/Safety of Cilta-Cel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline ASCT: Updated Follow-Up From CARTITUDE-2 Cohort D

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03477-9

Yaël Cohen, Tessa Kerre, Michel Delforge, María-Victoria Mateos, Jesús San-Miguel, Mounzer Agha, Shambavi Richard, Melissa Alsina, Mohamed Amine Bayar, Bheemshankar Chelluri, Katherine Li, Lee Jablow, Helen Varsos, Christina Corsale, Ioanna Tsakos, Kevin De Braganca, Ana Caroline Costa Sa, Tamar Lengil, Nikoletta Lendvai, Nitin Patel, Wilfried Roeloffzen

引用次数: 0

查看原文本刊更多论文

Cilta-Cel±来那度胺维持治疗对一线ASCT反应不佳的多发性骨髓瘤患者的疗效/安全性：来自CARTITUDE-2队列D的最新随访

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.